Roschier acts for TA Associates in connection with the public tender offer for Elos Medtech
TA Associates, through EM Intressenter, has announced a public offer to the shareholders of Elos Medtech to tender all their shares to EM Intressenter at a price of SEK 215 in cash per share, for a total amount of approximately SEK 1.7 billion. Roschier is legal advisor to TA Associates in connection with the offer.
The offer includes shares of both series A and B, and the acceptance period for the offer commenced on 14 June 2021 and expires on or about 5 July 2021. The total value of the offer, based on all 8,068,000 outstanding shares of series A and B in Elos Medtech, amounts to approximately SEK 1,735 million. The shares of series B in Elos Medtech are listed on Nasdaq Stockholm, Small Cap.
Elos Medtech is a global partner and specializes in medical technology and has extensive expertise in development, design and contract manufacturing of medical devices. Customers are primarily global medical technology companies. The Elos Medtech group’s operations are conducted in the following three business areas: Dental, Orthopedics and Life Science. Development, design and manufacturing takes place through five sites in Sweden, Denmark, USA and China, and Elos Medtech’s head office is situated in Gothenburg, Sweden.
TA Associates is a leading global growth-focused investment firm founded in 1968. Focused on targeted sectors within five industries – technology, healthcare, financial services, consumer and business services – TA Associates invests in profitable, growing companies with opportunities for sustained growth, and has invested in more than 535 companies around the world. TA Associates has offices around the world in Boston, Menlo Park, London, Mumbai and Hong Kong.
Roschier’s core advisory team comprised Ola Sandersson, Erik Persson, Miikka Kujanpää, Carl Ivars and Pontus Berganäs (Corporate & Capital Markets), Fredrik Rydin, Arvid Weimers and Sidar Långhavet (Finance & Restructuring), Kristian Hugmark (EU & Competition) and Elias Olsson (IP & Technology).